New Treatment Modalities in Hemophilia
Trends in Pediatrics · 2022
DOI: 10.4274/tp.2022.03521 ↗Kurz gefasst
Fachartikel in der Zeitschrift Trends in Pediatrics, 2022. Verfasst von Kaan Kavaklı. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Hemophilia is a single gene disorder and as a genetical coagulation system problem it is a life-long bleeding disorder. Even though routine treatment modalities as plasma-derived and then recombinant factor concentrates available for last 50 years, unmet needs is continuing for hemophilia therapy. Gold standart treatment is regularly prophylactic FVIII/FIX infusions. However, life-long and frequent intra-venous infusions become medical burden for patients and families. New agents as enhanced half-life (EHL) factor concentrates and non-factor therapies which are able to be used subcutaneously are very hopeful. In this review, EHL factor concentrates, FVIII mimetic agents and re-balancing therapies will be discussed. Although celluler gene therapy is very hopeful and successful phase-3 studies are reported, gene therapy for hemophilia will not be mentioned in this review.
Zitieren
APA
Kavaklı, K. (2022). New Treatment Modalities in Hemophilia. Trends in Pediatrics. https://doi.org/10.4274/tp.2022.03521
Vancouver
Kavaklı K. New Treatment Modalities in Hemophilia. Trends in Pediatrics. 2022. doi:10.4274/tp.2022.03521
BibTeX
@article{Kavakl2022,
author = {Kavaklı, Kaan},
title = {New Treatment Modalities in Hemophilia},
journal = {Trends in Pediatrics},
year = {2022},
doi = {10.4274/tp.2022.03521}
}
EUVIMED